live better, longer
Many women with osteoporosis eventually hear some version of this from their doctor:
“You need to start a bone drug.”
“You should stop hormones if you’re going on this medication.”
“Don’t start HRT while using an osteoporosis drug.”
“The hormones may interfere with the medication.”
But is that actually true?
This question matters because more women are becoming open to hormone replacement therapy again, especially as we better understand the role of estradiol, progesterone, and androgens in bone, muscle, cardiovascular health, brain health, and overall health span.
At the same time, osteoporosis drugs can be necessary in some situations. These medications can be powerful tools, especially for someone at high fracture risk, actively fracturing, or losing bone quickly.
So the real question is not whether hormones or bone drugs are “good” or “bad.”
The better question is:
Can they work together?
And based on the available research, the answer appears to be yes in many cases.
Let’s walk through what we know.
When we talk about osteoporosis treatment, we have to zoom out.
The goal is not simply to improve a number on a DEXA scan.
The real goals are to:
That means we should not think about osteoporosis care as one tool in isolation.
Exercise, nutrition, protein, minerals, vitamin D, vitamin K, hormones, supplements, and medications may all play a role.
The best plan is often synergistic.
That means each intervention should support the others instead of being treated as if it exists in a vacuum.
Some women are told that if they start an osteoporosis medication, they should stop hormone replacement therapy or avoid starting it.
The reasoning is usually that the hormones might interfere with the drug, blunt the drug’s effect, or make it harder to interpret results.
But this idea often comes more from dogma than from strong evidence.
It may also come from the older way medicine separated treatments into categories:
But bone biology does not work that way.
Bone is living tissue. It responds to hormones, mechanical loading, nutrition, inflammation, medications, and metabolism.
So if hormones support bone metabolism, it does not make sense to automatically remove them when starting a bone drug, unless there is a specific medical reason to do so.
Hormone replacement therapy is often framed as a treatment for hot flashes and night sweats.
But estradiol does much more than control vasomotor symptoms.
Estradiol plays a role in:
Progesterone may also play a role in bone health, especially through its effect on osteoblast differentiation and bone-building activity.
Androgens like testosterone and DHEA may support muscle and bone in the right person, at the right dose, with proper monitoring.
So if a woman is using hormones safely and appropriately, removing them during osteoporosis drug treatment may remove an important support system.
Before we ask whether HRT can be combined with bone drugs, we need to understand that not all bone drugs work the same way.
The major drug categories include:
Antiresorptives slow bone breakdown.
This category includes:
These drugs primarily work by reducing osteoclast activity. Osteoclasts are the cells that break down bone.
Anabolic drugs stimulate bone formation.
This category includes:
These drugs primarily stimulate osteoblast activity. Osteoblasts are the cells that build bone.
Romosozumab, also known as Evenity, is somewhat different.
It blocks sclerostin, which can increase bone formation and reduce bone breakdown at the same time.
This dual effect is one reason Evenity can create large short-term changes in bone density.
But it is still a short-term tool and is typically limited to 12 months.
Evenity, or romosozumab, is one of the most powerful osteoporosis drugs available.
It can increase bone formation and reduce bone breakdown at the same time.
That dual effect makes it interesting when thinking about HRT, because estradiol and progesterone also influence both sides of bone metabolism.
Estradiol primarily helps slow bone loss, but it also supports osteoblast function. Progesterone may support osteoblast activity. Together, they can create a hormonal environment that is more favorable for bone.
A small study from Korea looked at women using romosozumab and examined outcomes in those who were also on hormone therapy. Many of the women in that study were using tibolone, which is not available in the United States but is used in other countries.
Tibolone is a synthetic hormone therapy with estrogenic, progestogenic, and some androgenic effects.
In that study, women using romosozumab plus hormone therapy appeared to have greater bone density improvements than those using romosozumab without hormone therapy.
The study was small, so we should not overstate it.
But the direction makes sense biologically.
Hormones and romosozumab may be working in a supportive, synergistic way rather than canceling each other out.
Forteo and Tymlos are anabolic drugs.
They are designed to stimulate bone building.
This is especially important for people who need to build bone quickly or who are at higher fracture risk.
A study looking at teriparatide, also known as Forteo, examined women who were stable on HRT and compared outcomes with or without teriparatide.
The findings were encouraging.
Women on HRT alone had some improvement in spine bone mineral density. Women who started HRT also showed improvement. But women who used HRT plus teriparatide had much larger gains, especially at the spine.
The combination appeared to be synergistic.
That means the drug did not appear to lose effectiveness because of hormone therapy. Instead, the combination appeared to perform better than hormones alone.
This makes sense.
If anabolic therapy stimulates bone building and hormones improve the environment in which bone is being remodeled, the two can work together.
This does not mean every woman on HRT should take an anabolic drug.
It means women should not automatically be told that they must stop HRT in order for an anabolic drug to work.
Bisphosphonates are antiresorptive drugs.
They include medications like:
These drugs slow down bone breakdown.
This is where some people assume there could be conflict, because estradiol also helps slow bone breakdown.
The concern might sound like this:
“If estrogen already slows bone breakdown, and the bisphosphonate also slows bone breakdown, maybe they interfere with each other.”
But the available data does not support that concern.
Several studies have looked at estrogen or HRT combined with alendronate.
The general pattern is that the combination improves bone mineral density more than either therapy alone, especially at the spine.
In other words, estrogen and bisphosphonates appear to be synergistic rather than antagonistic.
That is important because many women are told to stop hormones when starting a bisphosphonate, but the research does not clearly justify that blanket recommendation.
If a woman is safely using HRT and then needs a bisphosphonate, there may be no reason to remove hormones purely out of fear that they will block the drug.
Prolia, or denosumab, is another antiresorptive drug, but it works differently than bisphosphonates.
It has a powerful effect on osteoclast suppression.
Unfortunately, there does not appear to be strong direct research on combining Prolia with HRT in the same way we have some data for bisphosphonates, teriparatide, and romosozumab.
That does not mean HRT cannot be used with Prolia.
It means we have less direct evidence.
Clinically, this is an area where we need more research.
Prolia is already a medication that requires careful long-term planning because stopping it abruptly can lead to rapid bone loss and increased fracture risk. So if a woman is on Prolia, her overall strategy needs to be very carefully managed.
HRT may still be appropriate for some women on Prolia, but the conversation should be individualized.
The word synergy matters here.
In osteoporosis care, we should not be asking:
“What one thing fixes this?”
We should be asking:
“What combination of tools creates the best environment for stronger bones and lower fracture risk?”
Bone health is influenced by many levers:
A medication may reduce fracture risk, but it does not replace the need for muscle.
HRT may support bone metabolism, but it does not replace the need for resistance training.
Exercise may stimulate bone, but it does not replace the need for protein, nutrients, and hormone support.
The best results often come when the right tools are layered together.
It is important to say this clearly:
There is a time and place for osteoporosis drugs.
Some people are at high enough fracture risk that waiting for lifestyle, nutrition, exercise, and hormones to work may not be wise.
Bone drugs may be appropriate when someone has:
Using a drug is not a failure.
The problem is not that drugs exist.
The problem is when drugs are used without a long-term plan, without addressing root causes, or while removing other supportive tools unnecessarily.
HRT can be powerful, but it is not appropriate for everyone.
Hormone therapy decisions should consider:
Some women may not be good candidates for systemic estrogen.
Others may be candidates but need careful monitoring.
Some may use progesterone or androgens selectively. Some may benefit from local vaginal estrogen but not systemic therapy.
The point is not that every woman must use HRT.
The point is that women who are appropriate candidates should not automatically be told to stop HRT just because they are using a bone drug.
If your doctor recommends an osteoporosis medication and tells you to stop or avoid HRT, ask thoughtful questions.
You might ask:
These are not confrontational questions.
They are reasonable questions.
You are asking for the logic behind the plan.
Hormones and osteoporosis drugs do not appear to be enemies.
Based on available data, HRT appears to be synergistic with several osteoporosis drug categories, including romosozumab, teriparatide, and bisphosphonates.
For Prolia, we need more direct research, but there is not enough evidence to say HRT must automatically be avoided.
The bigger issue is that osteoporosis treatment should be individualized.
If a woman is safely using HRT, and she also needs an osteoporosis drug, the conversation should be about how to build the best long-term strategy, not whether one tool must automatically replace the other.
Because the goal is not to win an argument about hormones or drugs.
The goal is to build stronger bones, reduce fracture risk, and support health span.
If you are trying to decide whether HRT, osteoporosis medications, or a combination approach is right for you, start with education.
Inside The OsteoCollective, we help members understand the bigger picture of bone health, including hormones, medications, exercise, nutrition, testing, and long-term fracture prevention.
Because osteoporosis is not the end.
But deciding to reverse it is the beginning.
This content is for educational purposes only and is not medical advice. Hormone therapy and osteoporosis medications require individualized medical decision-making. Do not start, stop, or combine HRT with osteoporosis medications without working with a qualified healthcare professional who understands your medical history, fracture risk, cardiovascular risk, cancer history, medications, labs, imaging, and treatment goals.
Your Blueprint for Lasting Bone Health and Longevity
.svg)
.svg)
.svg)
.svg)
Join us LIVE August 27th, 2026 at 3:00pm EST to Learn Dr. Doug's proven framework for Osteoporosis Reversal for FREE. Yes! Reversing Osteoporosis is possible and has happened for hundreds of Dr. Doug's patients.
If you have been blind-sided, feel stuck, confused, and exhausted with your diagnosis, this Masterclass is for you!
.svg)
.svg)
